Abstract
Uremic toxins are known to affect the regenerative properties of tissue-resident and circulating stem cells and thus appear to be a limiting factor for autologous stem cell-based approaches for treating chronic kidney disease. The recent article by van Koppen and colleagues in Stem Cell Research & Therapy provides evidence that an ex vivo short-term pre-treatment with statins reverts the dysfunction of bone marrow stem cells isolated from rats with renal impairment. Indeed, statin pre-treated cells improved renal function in a model of established chronic kidney disease. Our commentary discusses the potential of this approach in the context of autologous cell therapy and the available knowledge on the mechanisms involved in uremia-induced stem cell dysfunction.
Highlights
Uremic toxins are known to affect the regenerative properties of tissue-resident and circulating stem cells and appear to be a limiting factor for autologous stem cell-based approaches for treating chronic kidney disease
The recent article by van Koppen and colleagues [1] in Stem Cell Research & Therapy reports an interesting ex vivo approach aimed at overcoming the regenerative impairment of bone marrow stem cells (BMCs) isolated from Chronic kidney disease (CKD) rats (CKD BMCs)
Pre-treated cells administered in a single dose to rats with an established CKD showed a therapeutic efficacy in vivo that was similar to that of BMCs isolated from healthy rats
Summary
Uremic toxins are known to affect the regenerative properties of tissue-resident and circulating stem cells and appear to be a limiting factor for autologous stem cell-based approaches for treating chronic kidney disease. The autologous source of stem cells appears to be of reduced therapeutic interest for patients with CKD, as these cells partially lack regenerative potential. The uremic toxic milieu may affect stem cells isolated from healthy subjects once injected in patients with CKD.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
